West Pharmaceutical Services Inc (WST) Stock Price & Analysis
West Pharmaceutical Services Inc (WST) fell 7.67% to USD 328.2 as of July 25, 2026 at 01:12 UTC, according to Nexqual real-time market data.
WST last closed at USD 355.48; the session ranged USD 328.12–351.74 on volume of 1,303,901 shares. Market capitalization is $23.10B, with a 52-week range of USD 223.83–386 (NYQ). Source: Nexqual, July 25, 2026 at 01:12 UTC.
Key Statistics (as of July 25, 2026 at 01:12 UTC)
| Price | USD 328.2 |
|---|---|
| Change | ▼ 7.67% (down) |
| Previous Close | USD 355.48 |
| Open | USD 351.79 |
| Day Range | USD 328.12 – 351.74 |
| 52-Week Range | USD 223.83 – 386 |
| Volume | 1,303,901 shares |
| Market Cap | $23.10B |
| Exchange | NYQ |
Technical Analysis (WST)
Nexqual's technical model rates WST "NEUTRAL" based on 3 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 01:12 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 38 (neutral) |
| vs SMA50 | Below (USD 334.74) |
| MACD | 3.91 (positive) |
Analyst Ratings (WST)
Wall Street analysts rate WST "Strong Buy" based on 14 analysts, with a mean price target of USD 397.29 (range USD 340–447), per Nexqual as of July 25, 2026 at 01:12 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 397.29 |
| High Target | USD 447 |
| Low Target | USD 340 |
| Buy / Hold / Sell | 14 / 2 / 0 |
Earnings (WST)
| Next Earnings Date | 2026-10-22 |
|---|---|
| EPS Estimate | USD 2.17 |
| Revenue Estimate | $824.69M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 2.37 vs est 2.08 ▲ beat |
| 2026-03-31 | USD 2.13 vs est 1.68 ▲ beat |
| 2025-12-31 | USD 2.04 vs est 1.83 ▲ beat |
| 2025-09-30 | USD 1.96 vs est 1.71 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Financials & Fundamentals (WST)
| Total Revenue | $3.33B |
|---|---|
| Revenue Growth (YoY) | +13.80% |
| Gross Margin | +36.79% |
| Operating Margin | +20.53% |
| Profit Margin | +16.98% |
| ROE | +19.09% |
| Debt / Equity | 10.44 |
| Current Ratio | 2.82 |
| Total Cash | $435.80M |
| Total Debt | $312.10M |
| Free Cash Flow | $275.16M |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Ownership (WST)
| Insider Ownership | +0.64% |
|---|---|
| Institutional Ownership | +104.09% |
| Shares Outstanding | 70.38M |
| Float | 69.92M |
| Short % of Float | +3.83% |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
From West Pharmaceutical Services Inc's Latest SEC 10-K Filing (filed 2026-02-17)
Key Strengths & Strategy (as disclosed to the SEC)
- In addition to our Proprietary Products product portfolio, we provide our customers with a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support.
- Our products include a variety of primary proprietary packaging, containment solutions, reconstitution and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services and integrated solutions.
- Proprietary Products Segment Our Proprietary Products reportable segment offers elastomers & primary containment, drug delivery devices, integrated systems, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers.
- This focus on quality includes a commitment to excellence in manufacturing, scientific and technical expertise and management, which enables us to partner with our customers in order to deliver safe, effective drug products to patients quickly and efficiently.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| STE | STERIS plc (Ireland) | USD 214.07 | ▲ 1.66% |
| MTD | Mettler-Toledo International, I | USD 1,327.18 | ▲ 3.21% |
| TFX | Teleflex Incorporated | USD 132.1 | ▼ 2% |
| ROP | Roper Technologies, Inc. | USD 367.34 | ▲ 9.1% |
| COO | The Cooper Companies, Inc. | USD 70.31 | ▼ 0.27% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:12 UTC. This page is informational and not investment advice.